Ginkgo Biloba: The Independent Evidence Is Null (and What Actually Isn't)

By Erin Rose · Updated July 17, 2026 · Methodology

Educational overview — not medical advice. Ginkgo has a real bleeding-risk mechanism and a seizure caution; stop it 1–2 weeks before surgery and clear it with your clinician if you take anticoagulants — see does it work.

As an Amazon Associate we earn from qualifying purchases. Tiered by extract identity and ginkgolic-acid disclosure, never commissions.

Start here

What ginkgo is — and what the evidence actually supports

Ginkgo biloba leaf extract is sold as a memory and circulation aid, and it's one of the most-studied botanicals in existence. That's exactly why the honest read is sobering: with a lot of good trials done, the most independent, best-powered results came back negative. The Cochrane systematic review concluded the evidence that ginkgo helps cognition or dementia is "inconsistent and unreliable" (Birks 2009). And the two landmark prevention trials — designed to see whether ginkgo could stop dementia developing — both failed: GEM found a hazard ratio of 1.12 for dementia over ~6 years in 3,069 adults (DeKosky 2008), and GuidAge found no significant effect over 5 years in 2,854 adults (Vellas 2012).

The narrow signal that does survive

It isn't all null — but the positive evidence is specific and worth stating with its caveats. Meta-analyses of the EGb 761 extract at 240 mg/day for people who already have mild-to-moderate dementia found benefits for cognition and daily function (Tan 2015; Gauthier 2014). Two things keep this honest. First, it's treatment, not prevention — the same 240 mg dose that failed to prevent dementia is where the treatment signal appears. Second, several of these analyses have manufacturer-affiliated authors, which we disclose rather than launder. So the fair summary is: a modest, narrow benefit for one extract in one population, not a general cognitive enhancer.

The moat, in brief: extract identity + ginkgolic-acid disclosure

Because the evidence is EGb 761 specific, the extract you buy matters more than the milligram number. EGb 761 (Dr. Willmar Schwabe) is standardized to ~24% flavone glycosides, ~6% terpene lactones, and to under 5 ppm of ginkgolic acids — allergenic, cytotoxic contaminants that pharmacopeias cap at <5 ppm (van Beek 2009; Boateng 2022). A generic "24%/6%" extract looks identical on the label but isn't the trial material and rarely says anything about ginkgolic acids. Among the generics, only 2 actually print a ginkgolic-acid figure (Doctor's Best Extra Strength Ginkgo Biloba 120 mg (120 Veggie Caps) (<5 ppm) and Life Extension Ginkgo Biloba Certified Extract 120 mg (365 Veg Caps) (<1 ppm)). The full breakdown is on EGb 761 vs generic.

Safety worth respecting

Ginkgo is generally well tolerated, but two cautions are real. Its ginkgolide B inhibits platelet-activating factor, the rationale for a bleeding risk: case reports describe spontaneous and perioperative bleeding (Bent 2005), though controlled studies found no significant hemostatic effect when ginkgo was combined with aspirin or warfarin (Bone 2008) — a genuine tension, not a settled harm. There's also a seizure caution, after two people with epilepsy relapsed on ginkgo (Granger 2001). Practical rules: stop ginkgo 1–2 weeks before surgery, and clear it with your clinician if you take anticoagulants/antiplatelets or have a seizure disorder. The full safety section is on does it work.

Frequently asked questions

Related guides

• Ginseng — another botanical where the extract identity (species + ginsenoside %) is the whole game
• Rhodiola — the standardization problem again (rosavins vs salidroside disclosure)
• Lion's Mane — "which extract is real" for a nootropic mushroom

Sources